A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.

ABSTRACT: Timely and accurate identification of molecular alterations in solid tumors is essential for proper management of patients with advanced cancers. This has created a need for rapid, scalable comprehensive genomic profiling (CGP) systems that detect an increasing number of therapeutically-relevant variant types and molecular signatures. In this study, we assessed the analytical performance of the TruSight Oncology 500 High-Throughput assay for detection of somatic alterations from formalin-fixed paraffin-embedded tissue specimens. In parallel, we developed supporting software and automated sample preparation systems designed to process up to 70 clinical samples in a single NovaSeq 6000TM sequencing run with a turnaround time of <7 days from specimen receipt to report. The results demonstrate

SUBMITTER: Conroy JM 

PROVIDER: S-EPMC8639101 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature